Hope for new heart failure drugs

A revolutionary new drug could help prevent some of the damage that occurs after heart attack, British researchers hope.

Laboratory studies of the drug MitoSNO have proved promising, according to Cambridge University scientists.

The drug has been designed to prevent damage known as reperfusion injury, caused when the blood returns to damaged heart tissue.

Scientists hope it may form the basis for treating other similar injuries, such as stroke, when the tissue is starved of oxygen.

The drug works by accumulating rapidly inside the mitochondria of the heart cells and switching it off briefly. This prevents the cells reacting to the return of the blood supply by releasing free radicals – loose oxygen molecules.

The research was reported in the journal Nature Medicine.

Dr Mike Murphy, of the UK Medical Research Council, said: "We are hopeful that if human trials of MitoSNO are successful it could eventually be used in many other areas of medicine."

Fellow researcher Dr Thomas Krieg, from Cambridge University, said: "There have been some important advances in cardiac medicine in recent years and as a result more people now survive a heart attack than ever before. However, we still have no effective treatments to protect against reperfusion injury.

"By preserving more of the healthy heart tissue, we hope that we can give people who survive a heart attack an improved quality of life."

Dr Shannon Amoils, of the British Heart Foundation, which backed the research, said: “This drug is promising as it could potentially treat people immediately after a heart attack when blood flow to the heart is restored as part of routine treatment.

"This could mean fewer heart attack survivors go on to live with the burden of heart failure, which for many is a debilitating and distressing condition.”

* A single drug has become the first to improve survival of heart failure patients in ten years, a major conference heard.

Coenzyme Q10 is found naturally in the body and like MitoSNO works in the mitochondria, where it is an anti-oxidant and releases energy.

Findings of studies involving patients were reported to the Heart Failure 2013 conference in Lisbon, Portugal.

Researcher Professor Svend Aage Mortensen, from Copenhagen, Denmark, said: “CoQ10 is the first medication to improve survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to standard heart failure therapy.”

Chouchani et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex. Nature Medicine 26 May 2013 doi:10.1038/nm.3212

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index